Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025

Core Insights - Kuros Biosciences achieved a significant 72% year-over-year sales growth, reaching USD 146.1 million for the year 2025, driven primarily by strong performance in Direct MagnetOs sales [2][4][6]. Financial Highlights - Total group revenue for 2025 was USD 146.1 million, an increase of USD 60.9 million from 2024 [2][6]. - Direct MagnetOs sales rose by 71% to USD 143.9 million, compared to USD 84.3 million in 2024 [2][6]. - EBITDA increased to USD 12.4 million in 2025, up from USD 2.4 million in 2024, with adjusted EBITDA reaching USD 19.6 million and a margin of 13.4% [3][6]. - The company reported its first-ever net profit of USD 2.6 million in 2025, compared to a net loss of USD 4.8 million in 2024 [3][6]. Operational Highlights - The company expanded its commercial reach and introduced new products while maintaining operational discipline [4]. - Kuros initiated commercial expansion into the USD 1.3 billion extremities market and enrolled the first patient in a significant clinical trial [7]. - The FDA granted clearance for the MagnetOs MIS Delivery System, supporting minimally invasive surgery [7][8]. Cost Structure - Cost of goods sold amounted to USD 18.6 million in 2025, up from USD 15.2 million in 2024 [9]. - Sales and marketing costs increased significantly from USD 50.7 million in 2024 to USD 84.5 million in 2025, reflecting the growth in commercial activities [10]. - Research and development costs rose from USD 7.9 million in 2024 to USD 10.7 million in 2025, driven by increased clinical trial expenditures [11]. Financial Position - Cash and cash equivalents stood at USD 19.8 million, with total funds available for operations amounting to USD 60.0 million as of December 31, 2025 [12]. - Total intangible assets were USD 16.6 million, and goodwill was USD 24.3 million as of December 31, 2025 [13]. Future Outlook - Kuros expects at least 35% sales growth in 2026, with an adjusted EBITDA margin of around 14% [6][14]. - By 2028, the company anticipates sales of USD 300 to 330 million, with an adjusted EBITDA margin of at least 20% [6][14].